Publication: Prognostic role of IRS-4 in the survival of patients with pancreatic cancer
Authors
Ortega, Miguel A ; Pekarek, Leonel ; Garcia Montero, Cielo ; Fraile Martinez, Oscar ; Saez, Miguel A ; Asúnsolo, Angel ; Alvarez Mon, Miguel A ; Monserrat, Jorge ; Coca, Santiago ; Toledo Lobo, M. Val ; García Honduvilla, Natalio ; Albillos, Agustin ; Buján, Julia ; Alvarez Mon, Melchor ; Guijarro, Luis G
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia, Departamento de Biologia Celular e Histiologia
publication.page.editor
publication.page.department
DOI
https://doi.org/10.14670/HH-18-432
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Pancreatic cancer is a malignancy of rising
incidence, especially in developed countries due to
causes such as sedentary lifestyles, tobacco smoking and
ultraprocessed high fat and high sugar diets, amongst
others. It is in fact the 7th cause of cancer-related deaths
worldwide, and, in the following years, it is expected to
climb upwards to 2nd position, after lung cancer. This is
because it may have an asymptomatic course, and when
it becomes evident it is in advanced stages, accompanied
by metastasis generally. For this reason, survival rates
are so low and, even in the few successful cases there is
a high possibility of recurrence. Identifying new
molecular biomarkers is arising as a highly useful tool
for pancreatic cancer clinical management, although
much research and work remain to be done in this field.
Thus, the present study aims to analyze a series of
molecules (IRS-4, Rb1, Ki-67 y COX-2) as candidates
for prognosis and survival by immunohistochemistry
techniques. Additionally, a 60-month longitudinal
surveillance program was conducted, associated with
diverse clinical parameters. Kaplan-Meier curves
estimating the time of survival according to tumoral
expression of those molecules denoted a low cumulative
survival rate. Importantly, we observed that high levels
of IRS-4 were significantly associated with a bad
prognosis of the disease, increasing 160 times the
mortality risk. In this way, our research showed a
relevant value of these biomarkers in pancreatic cancer
patients’ survival, opening a pathway for future research
areas designed to inhibit these components
publication.page.subject
Citation
Histology and Histopathology Vol. 37, nº5 (2022)
item.page.embargo
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/